Food and Drug Administration

Food Advisory Committee

March 18-19, 2003

Slides

Current Marketing and use of Powdered Infant Formula in the United States, Dr. Sue Ann Anderson, PhD, FDA (HTM) (PPT)

Microbial Detection of Enterobacter sakazakii: Food and Clinical, Donald Burr, FDA (HTM) (PPT)

Residance - Thermal and Other, Robert Buchanan, FDA (HTM) (PPT)

Clinical Consequences of Enterobacter sakazakii Infections, Dr. John Alexander, MD, MPH, FDA (HTM) (PPT)

Enterobacter sakazakii Case Reports and Outbreaks Involving Infants as Reported in the Peer-Reviewed English Medical Literature, Karl C. Klontz, FDA (HTM) (PPT)

FDA Field Survey of Powdered Formula Manufacturing, Dr. Don Zink, FDa (HTM) (PPT)

Enterobacter sakazakki meningitis and death associated with powdered infamt formula, Matthew Kuehnert, National Center for Infectious Diseases (HTM) (PPT)

Enterobacter sakazakii General Microbiology, Maria Nazarowec-White PhD, Canadian Food Inspection Agency (HTM) (PPT)